Published in J Virol on August 22, 2007
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol (2009) 1.35
Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine (2010) 1.33
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One (2011) 1.28
A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol (2012) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08
L2, the minor capsid protein of papillomavirus. Virology (2013) 1.07
The role of furin in papillomavirus infection. Future Microbiol (2009) 1.06
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine (2010) 1.05
HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med (2010) 1.03
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol (2009) 1.00
Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med (2015) 0.98
Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol (2013) 0.97
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
Optimization of multimeric human papillomavirus L2 vaccines. PLoS One (2013) 0.95
Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 0.92
Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2. Am J Pathol (2008) 0.92
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J Virol (2013) 0.92
Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines (2013) 0.90
Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine (2009) 0.86
Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs. PLoS One (2012) 0.86
Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. Virol J (2008) 0.84
Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) (2014) 0.84
Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One (2011) 0.83
A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types. PLoS One (2015) 0.81
The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnol Bioeng (2014) 0.81
Papillomavirus capsid proteins mutually impact structure. Virology (2011) 0.81
Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes. Vaccine (2014) 0.81
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. PLoS One (2014) 0.81
Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccine. Clin Vaccine Immunol (2013) 0.79
New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir Ther (2011) 0.79
The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane. Virology (2015) 0.78
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. J Virol (2016) 0.78
A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types. PLoS One (2014) 0.78
Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Virol J (2015) 0.77
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes. Vaccine (2015) 0.77
A multimeric L2 vaccine for prevention of animal papillomavirus infections. Virology (2011) 0.76
Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies. Clin Vaccine Immunol (2015) 0.76
Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res (2016) 0.76
Spontaneous and vaccine-induced clearance of Mus musculus Papillomavirus type 1 (MmuPV1/MusPV1) infection. J Virol (2017) 0.75
Protein transduction domain can enhance the humoral immunity and cross-protection of HPV16L2 peptide vaccines. Biomed Rep (2016) 0.75
HPV vaccine: One, two, or three doses for cervical cancer prevention? Indian J Med Paediatr Oncol (2016) 0.75
Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines (2016) 0.75
Recent advances in preclinical model systems for papillomaviruses. Virus Res (2016) 0.75
Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One (2017) 0.75
Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies. Curr Protoc Microbiol (2015) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Classification of papillomaviruses. Virology (2004) 14.16
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer (2004) 6.99
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol (1993) 4.00
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci U S A (2006) 2.64
Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology (1992) 2.53
Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol (1990) 2.34
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 2.25
The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology (1991) 2.24
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol (1996) 1.94
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol (1999) 1.66
Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol (1994) 1.60
Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49
Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol (2002) 1.48
Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology (1995) 1.48
Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology (1996) 1.45
Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol (2001) 1.44
Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol (1996) 1.32
Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem (2003) 1.27
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26
A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology (1997) 1.22
Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev (2005) 1.17
Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine (2001) 1.15
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine (2006) 1.10
Vaccination against papillomavirus in cattle. Clin Dermatol (1997) 1.06
Laboratory production of infectious stocks of rabbit oral papillomavirus. J Gen Virol (1996) 0.93
Protective cell-mediated immunity by DNA vaccination against Papillomavirus L1 capsid protein in the Cottontail Rabbit Papillomavirus model. Viral Immunol (2006) 0.92
Linear B-cell epitopes in the N-terminus of L2 of bovine papillomavirus type 4. Res Vet Sci (1997) 0.81
Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med (2009) 8.26
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet (2011) 3.52
Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis (2004) 3.04
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis (2010) 2.70
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol (2008) 2.51
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol (2007) 2.27
In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe (2010) 2.24
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS (2012) 2.15
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol (2003) 2.02
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Practice patterns in cervical cancer screening and human papillomavirus testing. Am J Clin Pathol (2012) 1.81
Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One (2011) 1.80
Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet (2002) 1.78
Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem (2007) 1.77
Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology (2005) 1.73
Circumcision of HIV-infected men and transmission of human papillomavirus to female partners: analyses of data from a randomised trial in Rakai, Uganda. Lancet Infect Dis (2011) 1.69
Cell surface-binding motifs of L2 that facilitate papillomavirus infection. J Virol (2003) 1.68
Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol (2006) 1.67
Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis (2005) 1.65
Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection. J Virol (2005) 1.61
Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol (2008) 1.59
Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali. Clin Infect Dis (2011) 1.55
Absence of simian virus 40 in human brain tumors from northern India. Int J Cancer (2002) 1.50
Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol (2002) 1.48
Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res (2003) 1.46
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev (2008) 1.44
Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev (2003) 1.44
Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns. Reprod Sci (2007) 1.43
Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. Sex Transm Dis (2007) 1.43
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (2002) 1.42
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res (2006) 1.41
The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS (2010) 1.40
Kinetics of in vitro adsorption and entry of papillomavirus virions. Virology (2004) 1.37
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol (2008) 1.35
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res (2008) 1.33
Propagation, infection, and neutralization of authentic HPV16 virus. Virology (2004) 1.32
Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res (2012) 1.31
Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res (2006) 1.28
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol (2003) 1.27
Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol (2004) 1.27
Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem (2003) 1.27
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol (2008) 1.26
Varicella-zoster virus infection induces autophagy in both cultured cells and human skin vesicles. J Virol (2009) 1.26
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Quantitative RT-PCR assay for HPV infection in cultured cells. J Virol Methods (2003) 1.23
A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis (2004) 1.23
Association between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy. Menopause (2014) 1.21
Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer (2005) 1.19
Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer (2003) 1.19
Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol (2009) 1.18
The viral E4 protein is required for the completion of the cottontail rabbit papillomavirus productive cycle in vivo. J Virol (2004) 1.18
Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med (2011) 1.18
Male circumcision and anatomic sites of penile high-risk human papillomavirus in Rakai, Uganda. Int J Cancer (2011) 1.17
Human papillomavirus genotype prevalence in high-grade squamous intraepithelial lesions and colposcopically normal women from Zimbabwe. Int J Cancer (2002) 1.17
Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol (2003) 1.16
B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol (2005) 1.16
Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits. J Virol (2002) 1.15
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14
Human papillomavirus type distribution in cervical cancer in Delhi, India. Int J Gynecol Pathol (2006) 1.13
Cancer patterns in nasopharyngeal carcinoma multiplex families in Taiwan. Int J Cancer (2009) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Papillomavirus infection requires gamma secretase. J Virol (2010) 1.12
Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol (2008) 1.12
Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol (2009) 1.12
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol (2003) 1.11
Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection. J Virol Methods (2007) 1.11
Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10
Impact of genetic changes to the CRPV genome and their application to the study of pathogenesis in vivo. Virology (2006) 1.10
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine (2006) 1.10
Suitability of self-collected vaginal samples for cervical cancer screening in periurban villages in Andhra Pradesh, India. Cancer Epidemiol Biomarkers Prev (2009) 1.10
An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J Immunol (2006) 1.09
Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol (2006) 1.08
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One (2012) 1.08